TY  - JOUR
AU  - Rizzo, Manfredi
AU  - Vekić, Jelena
AU  - Koulouris, Spyridon
AU  - Zeljković, Aleksandra
AU  - Jelić-Ivanović, Zorana
AU  - Spasojević-Kalimanovska, Vesna
AU  - Rini, Giovam Battista
AU  - Sakellariou, Dimitrios
AU  - Pastromas, Socrates
AU  - Mikhailidis, Dimitri P.
AU  - Manolis, Antonis S.
PY  - 2010
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1398
AB  - Rosiglitazone may increase cardiovascular risk in patients with type 2 diabetes. Yet, its effects on atherogenic dyslipidemia are still not fully elucidated. In a prospective open-label study rosiglitazone (4 mg/day for 12 weeks) was added to a maximum of 2 oral antidiabetic drugs in 18 diabetic patients. We evaluated the effects on plasma lipids before and after an oral fat load. The size and subclasses of low-density lipoprotein (LDL) and high-density lipoprotein (HDL) were also determined (by gradient gel electrophoresis). Rosiglitazone improved glycosylated hemoglobin ([HbAlc] P = .0023), without significant effects on fasting and postprandial plasma lipids. Fasting LDL size increased (+1.4%, P = .034), with less small, dense LDL-IIIA (-25.1%, P = .018). Postprandially, larger HDL-2b reduced (-8.7%, P = .006) and smaller HDL-3b increased (+12.2%, P = .05), without any effects on HDL size. Rosiglitazone led to antiatherogenic changes in LDL size and subclasses, with proatherogenic changes in HDL subclasses, despite no effects on plasma lipids. Their clinical relevance remains to be established.
PB  - Sage Publications Inc, Thousand Oaks
T2  - Angiology
T1  - Effects of Rosiglitazone on Fasting and Postprandial Low- and High-Density Lipoproteins Size and Subclasses in Type 2 Diabetes
VL  - 61
IS  - 6
SP  - 584
EP  - 590
DO  - 10.1177/0003319710366431
ER  - 

@article{
author = "Rizzo, Manfredi and Vekić, Jelena and Koulouris, Spyridon and Zeljković, Aleksandra and Jelić-Ivanović, Zorana and Spasojević-Kalimanovska, Vesna and Rini, Giovam Battista and Sakellariou, Dimitrios and Pastromas, Socrates and Mikhailidis, Dimitri P. and Manolis, Antonis S.",
year = "2010",
abstract = "Rosiglitazone may increase cardiovascular risk in patients with type 2 diabetes. Yet, its effects on atherogenic dyslipidemia are still not fully elucidated. In a prospective open-label study rosiglitazone (4 mg/day for 12 weeks) was added to a maximum of 2 oral antidiabetic drugs in 18 diabetic patients. We evaluated the effects on plasma lipids before and after an oral fat load. The size and subclasses of low-density lipoprotein (LDL) and high-density lipoprotein (HDL) were also determined (by gradient gel electrophoresis). Rosiglitazone improved glycosylated hemoglobin ([HbAlc] P = .0023), without significant effects on fasting and postprandial plasma lipids. Fasting LDL size increased (+1.4%, P = .034), with less small, dense LDL-IIIA (-25.1%, P = .018). Postprandially, larger HDL-2b reduced (-8.7%, P = .006) and smaller HDL-3b increased (+12.2%, P = .05), without any effects on HDL size. Rosiglitazone led to antiatherogenic changes in LDL size and subclasses, with proatherogenic changes in HDL subclasses, despite no effects on plasma lipids. Their clinical relevance remains to be established.",
publisher = "Sage Publications Inc, Thousand Oaks",
journal = "Angiology",
title = "Effects of Rosiglitazone on Fasting and Postprandial Low- and High-Density Lipoproteins Size and Subclasses in Type 2 Diabetes",
volume = "61",
number = "6",
pages = "584-590",
doi = "10.1177/0003319710366431"
}

Rizzo, M., Vekić, J., Koulouris, S., Zeljković, A., Jelić-Ivanović, Z., Spasojević-Kalimanovska, V., Rini, G. B., Sakellariou, D., Pastromas, S., Mikhailidis, D. P.,& Manolis, A. S.. (2010). Effects of Rosiglitazone on Fasting and Postprandial Low- and High-Density Lipoproteins Size and Subclasses in Type 2 Diabetes. in Angiology
Sage Publications Inc, Thousand Oaks., 61(6), 584-590.
https://doi.org/10.1177/0003319710366431

Rizzo M, Vekić J, Koulouris S, Zeljković A, Jelić-Ivanović Z, Spasojević-Kalimanovska V, Rini GB, Sakellariou D, Pastromas S, Mikhailidis DP, Manolis AS. Effects of Rosiglitazone on Fasting and Postprandial Low- and High-Density Lipoproteins Size and Subclasses in Type 2 Diabetes. in Angiology. 2010;61(6):584-590.
doi:10.1177/0003319710366431 .

Rizzo, Manfredi, Vekić, Jelena, Koulouris, Spyridon, Zeljković, Aleksandra, Jelić-Ivanović, Zorana, Spasojević-Kalimanovska, Vesna, Rini, Giovam Battista, Sakellariou, Dimitrios, Pastromas, Socrates, Mikhailidis, Dimitri P., Manolis, Antonis S., "Effects of Rosiglitazone on Fasting and Postprandial Low- and High-Density Lipoproteins Size and Subclasses in Type 2 Diabetes" in Angiology, 61, no. 6 (2010):584-590,
https://doi.org/10.1177/0003319710366431 . .